At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 375 enrolled
Drug / intervention
SPARC1104 modified dose regimen I +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety Study of SPARC1104
In Brief
A Phase 3 clinical trial evaluating SPARC1104 modified dose regimen I, SPARC1104 modified dose regimen II, and 1 other intervention for Spasticity. Completed, enrolled 375 participants across 51 sites.
Detailed Summary
Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpasticity
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartApr 2013
Primary CompletionJul 2017
Study CompletionOct 2017
TodayJul 2026
First PostedFeb 22, 2013
Enrollment StartApr 9, 2013
Primary CompletionJul 1, 2017
Study CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 13.4 years ago
Interventions
SPARC1104 modified dose regimen Idrug
Subjects who exited study CLR\_09\_21
SPARC1104 modified dose regimen IIdrug
Subjects who received prior treatment regimen I
SPARC1104 modified dose regimen IIIdrug
Subjects who received no prior treatment regimen